A new autologous cell therapy maker is coming to the fore with $10 million to start. Chicago-based CTRL Therapeutics hopes to expand beyond the current scope of cancers treated by existing cell therapies and also introduce a less complex process for patients and manufacturers. CTRL is trying to build on